Roche's core research spans five large areas. Boris Zaïtra, who now leads corporate business development, is confident his team of dealmakers can juggle them.

JPM25 is in full swing as several pharma powerhouses—including Merck, Lilly and Amgen—detail their strategies for growth in ...

It's JPM 2025 and here at Fierce Biotech we’re bringing you all the latest updates live from the life sciences event of the ...

Trump administrations pro-corporation policies boost healthcare M&A prospects Healthcare investment outlook improves as Trump ...

Roche (RHHBY) said Monday that it has received 510(k) clearance from the U.S. Food and Drug Administration for its highly-sensitive ...

With the Stormers needing to win to retain an interest in the Champions Cup, some of the selections might surprise, with the exciting young Jonathan Roche, the Ikey-Tigers star centre from the ...

Roche Holding AG's acquisition of Poseida for $1.5bn is a smart move by Big Pharma as allogeneic cell therapies are becoming increasingly de-risked. Despite recent challenges, Roche's diverse ...

Citibank, N.A., the depositary for the tender offer, advised Roche that a total of approximately 64,991,586 shares of Poseida’s common stock were validly tendered and not validly withdrawn in the ...

On January 8, 2025, Poseida Therapeutics terminated its Loan and Security Agreement with Oxford Finance LLC and other lenders, effectively discharging all outstanding obligations. This termination was ...